Indication
Treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AMC-MRC)

Medicine details

Medicine name:
liposomal formulation of daunorubicin & cytarabine (Vyxeos)
SMC ID:
SMC2130
Pharmaceutical company
Jazz Pharmaceuticals
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
Q1 2019
SMC meeting date:
Q1 2019
Patient group submission deadline:
03 December 2018